Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Myeloid cells comprise a major component of the tumor microenvironment (TME) that promotes tumor growth and immune evasion. By employing a small-molecule inhibitor of glutamine metabolism, not only were we able to inhibit tumor growth, but we markedly inhibited the generation and recruitment of myeloid-derived suppressor cells (MDSCs). Targeting tumor glutamine metabolism led to a decrease in CSF3 and hence recruitment of MDSCs as well as immunogenic cell death, leading to an increase in inflammatory tumor-associated macrophages (TAMs). Alternatively, inhibiting glutamine metabolism of the MDSCs themselves led to activation-induced cell death and conversion of MDSCs to inflammatory macrophages. Surprisingly, blocking glutamine metabolism also inhibited IDO expression of both the tumor and myeloid-derived cells, leading to a marked decrease in kynurenine levels. This in turn inhibited the development of metastasis and further enhanced antitumor immunity. Indeed, targeting glutamine metabolism rendered checkpoint blockade-resistant tumors susceptible to immunotherapy. Overall, our studies define an intimate interplay between the unique metabolism of tumors and the metabolism of suppressive immune cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a prodrug of 6‐diazo‐5‐oxo‐l‐norleucine (DON) that blocks glutamine metabolism in myeloid precursor cells can differentiate monocytes into anti‐tumor TAMs, leading to tumor regression in mouse models [56].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx247 · Cited by 9,849
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · cited 1×
“Yet, in spite of these successes it is clear that not all cancers respond to checkpoint blockade alone and even amongst responsive cancers, not all patients respond (52, 60-62).”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Yet, in spite of these successes it is clear that not all cancers respond to checkpoint blockade alone and even amongst responsive cancers, not all patients respond (52, 60-62).”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 1×
“Such an environment favors the residency of suppressive myeloid cells such as MDSCs, TANs, and TAMs, all of which contribute to promoting tumor growth, angiogenesis, metastasis, and immune escape (51).”
BackgroundThe emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“Alternatively, suppressive immune cells, that are metabolically distinct from effector cells, thrive in the TME (1-3).”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
Background
Cited by
Items 401–471 of 471
Huang, L., Cai, B., Lin, Y., Hu, Z., & Fu, D. (2024) · Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agents · doi:10.23812/j.biol.regul.homeost.agents.20243809.468
Metabolomics perspectives for clinical medicine, volume II
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-6172-0
Immunomodulatory Mechanisms Impacting the Activity and Fate of Natural Killer Cells in Cancer
Bottino, C., Dondero, A., Vitale, C., & Castriconi, R. (2025) · Springer eBooks · doi:10.1007/978-3-662-68816-8_35-1
Recent advances in nanomedicine targeting amino acid metabolism for anti-tumor therapy
Pang, C., Song, X., Luo, Y., Li, H., Guo, W., Liu, W., Feng, H., Wu, Y., Chu, X., & Lei, Z. (2025) · Journal of Nanoparticle Research · doi:10.1007/s11051-025-06344-9
“Moreover, inhibition of glutamine metabolism significantly suppresses the generation and mobilization of MDSCs [37], further promoting the production of anti-tumor inflammatory cells.”
The Fundamentals of Cancer Immunity
Jia, H., Yang, L., & Liu, J. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837675739-00098 · Cited by 1
The 31st Annual Prostate Cancer Foundation Scientific Retreat Report
Miyahira, A. K., & Soule, H. R. (2025) · The Prostate · doi:10.1002/pros.70015
“TAMs are uniquely metabolically reliant on glutamine to sustain oxidative phosphorylation and suppress immune activation [26 – 28].”
He, S., Huang, J., Zheng, S., & Wu, Z. (2025) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2025.102028
Metabolic programming and immune suppression
Wang, Y., & Ma, L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00054-0
Bollino, D. R., Hameed, K. M., Bhat, A. G., Zarrabi, A., Casildo, A., Ma, X., Tighe, K. M., Carter‐Cooper, B., Strovel, E. T., Lapidus, R. G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26143689
Wang, L., Deng, C., Wu, Z., Zhu, K., & Yang, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26617519
Wu, Z., Li, N., Gao, Y., Cao, L., Yao, X., & Peng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.25017791
Shi, H., Yuan, X., Yang, X., Huang, R., Fan, W., & Liu, G. (2024) · Figshare · doi:10.6084/m9.figshare.26674445
Zhang, K., Li, Y.-J., Peng, L.-J., Gao, H.-F., Liu, L.-M., & Chen, H. (2024) · Figshare · doi:10.6084/m9.figshare.26560736
López Cabrera, E. (2024) · UCL Discovery (University College London)
Li, C., Tan, H., Mao, Y., Liu, Y., Hu, J., Pang, X., Hou, X., & Minglin, O. (2025) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-025-00695-y
“In most solid tumors, there is an increased requirement for glutamine metabolism, and glutamine accumulation in the tumor microenvironment of some solid tumors inhibits tumor-associated macrophage M1 polarization and thus assisting tumor cells in their immune escape (Oh et al. 2020).”
Gan, Y., Zhang, Y., Dong, X., & Lv, F. (2026) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.70038 · Cited by 1
RHOJ derived peptide promotes chemosensitivity by inhibiting glutamine metabolism in gastric cancer
Li, J., Li, H., Ye, F., Wang, J., Li, F., Bei, S., Zhang, X., Jiang, J. H., & Li, F. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07731-z
“Both basic and clinical trials have demonstrated that targeting tumor-dependent glutamine metabolism can effectively inhibit tumor growth, overcome tumor immune evasion and reverse drug resistance [49–51].”
Liu, Q., Zhang, K., He, S., Jia, X., Liu, J., Wu, D., & Ye, B. (2026) · Journal of Immunology Research · doi:10.1155/jimr/5577070
Kim, E. Y., Lim, D. C., Wang, Y., Kim, E. Q., Wu, C., Paul, A., Chen, C., & Wangpaichitr, M. (2026) · iScience · doi:10.1016/j.isci.2026.115037
Wogonin-derived chemotype enables discovery of novel GLS1 inhibitors with potent antitumor activity
Li, X., Liang, Y., Zhang, X., Wu, Y., Wu, T., Tian, Y., Tang, C., Qiu, Z., Wu, H., Bian, J., et al. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2642584
Amino Acids as Targets for Immunotherapy against Solid Tumors
da Costa, K. V. V., Passos, G. A., Botelho, R. J. S., Ruza, M. S. V., Dias-Lopes, G., & Silva, R. C. M. C. (2026) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-026-02050-y
“…in tumor-associated macrophages, which is correlated to advanced tumors [ 180 ]; promotes MDSCs recruitment and sup - pressive functions [ 181 ]; polarizes macrophages to M2 phenotype [183 ]; tumor cells-derived glutamate promotes aspartate synthesis by cancer associated fibroblasts,…”
The anti-tumoral effects of a low protein diet and of the IRE1α signaling
Turtos, A. M. (2022) · theses.fr (ABES) · doi:10.70675/fd90a3e8ze35az42fdzbd0ez966f12ddad22
Identification de nouvelles approches thérapeutiques pour les lymphomes T périphériques
Krug, A. (2023) · theses.fr (ABES) · doi:10.70675/a7d03ecfz08c1z4eb2z8979z0a3888d49669
Role of monocytes, macrophages, and polymorphonuclear cells in cancer immunology
Jain, P., Panchal, N., Finley, J., Gupta, S. K., Sandhu, J., & Aggarwal, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41551-7.00008-4
Targeting the Vim–PGI 2 Pathway Enhances CD8 + T Cell‐Mediated Antitumor Immunity in Breast Cancer
Quan, H., Shao, L., Li, Q., & Dong, C. (2026) · Human Mutation · doi:10.1155/humu/8880918
SLC7A7 Downregulation in Monocytes Drives Immunosuppression and Osteosarcoma Progression
Jiang, B., Zhu, H., & Zhang, Z. (2026) · International Journal of Genomics · doi:10.1155/ijog/8314828
史迎莉, Vicens, L. R., Teve, M., Slusher, B. S., Bishai, W. R., & Parveen, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.14.725218
Self-citationMetabolic Cross Talk in the Tumor Microenvironment
Das, C., Dash, S. R., Das, B., Chatterjee, S., & Parija, T. (2026) · Cancer treatment and research · doi:10.1007/978-3-032-21861-2_7
Impact of metabolic reprogramming on the immune response in hepatocellular carcinoma
Wang, Y., Lu, Y.-J., Zhou, J., & Yang, X.-R. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2025.105
Su, Y., Liang, Y., Zhong, D., Chen, Y., Ma, S. S., & Huang, X. (2026) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s616101 · Cited by 1
“45 Additional studies by Mano et al revealed that TAMs induce HGF expression and activate the c-Met signaling pathway, thereby enhancing the invasiveness of HCC cells.”
Zhang, J., Zhu, Y., Liu, G., Liao, M., Wu, J., Chen, C., Guo, M., Jiang, Y., Zhao, J., & Xu, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1806160
Huang, X., Xia, C., Jin, X., & Wang, Y. (2026) · Cancer Management and Research · doi:10.2147/cmar.s616696
“16”
Campos-Sandoval, J. A., Santos-Jiménez, J. D. L., Márquez, J., & Matés, J. M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070850
“Indeed, JHU083, is substantially less toxic than DON and, at a dose of 2 mg/kg, demonstrated excellent antitumor efficacy in murine models [94].”
Bhongade, B. A., Ali, A. A., El‐Tanani, M., Satyam, S. M., Talath, S., Wali, A. F., Rabbani, S. A., Ibraheem, W., Hoffmann, K., Арманович, А. А., et al. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48070723
“…therapies and immune-based treatments in oncology has recently opened exciting possibilities for the combination with glutaminase blocking agents (Figure 2), which, being a part of multi-modal treatment strategies, adds even more versatility to their initial value as single-agent therapy [74,82].”
Amino Acid and Lipid Metabolism in Cancer: Mechanisms and Therapeutic Opportunities
Wang, Z., Fu, X., Bai, J., Liu, Y., & Huang, K. (2026) · MedComm · doi:10.1002/mco2.70886
“A Journal of Clinical Investigation study reported that targeting glutamine metabolism can enhance tumor-specific immunity by modulating suppressive myeloid cells, supporting the idea that glutamine interventions may relieve myeloid-driven resistance features [ 143 ].”
Targeting antibody-inaccessible immune resistance with small-molecule immunotherapy
Zhu, J.-M., Liu, H.-M., Hu, J., Liu, Y., Li, S., Liu, H., Dai, X., Li, W., & Zheng, Y. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117165
Chen, A. L., Sun, W., Zhao, Y., Sun, D., Meng, T., Qi, Y., Jiang, F., Sun, J., Gao, Z., & Yu, D. (2026) · Advanced Science · doi:10.1002/advs.76673
d-serine as a metabolic immune checkpoint in the tumour microenvironment
Tsugaru, K., Suzuki, S., Miyamoto, K., 村上, 和., Chida, A., Kato, C., Fukasawa, N., Shigehara, A., Hasegawa, M., Yoshimatsu, Y., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106402
“Third, although several L-AAs influence immune responses through defined transporters and receptors during cancer progression, 9,65,66,95 we did not detect the expression of canonical D-ser–related receptors, such as NMDA receptors, on tumour-infiltrating immune cells in D-ser mice.”
Liu, Z., He, L., Tian, Y., Feng, S., Yang, X., Wu, H., Pu, Q., Wang, Y., & Yuan, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1871598
“Transient or partial inhibition may reduce tumor metabolic fi tness while preserving immune function, whereas prolonged systemic deprivation may suppress immune priming, effector expansion, and tissue homeostasis (25, 261).”
Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy
Ge, X., Han, D., Wang, J., Dai, X., Ma, C., & Chen, F. (2026) · MedComm · doi:10.1002/mco2.70882
Targeting Immune Cell Metabolism for Cancer Immunotherapy
Jiang, Y., Wu, Y.-L., & Ying, T.-L. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i3.48
Neutrophil‐based immunotherapy: A metabolic lens on mechanisms and therapeutic implications
Xu, W., Su, Y., Zhou, L., Liu, J., & Guo, J. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70780
“122,123 Despite promising preclinical efficacy, multiple obstacles hinder clinical translation.”
Self-citationYu, Y. C., Sung, Y., Lim, S. H., Kwon, J. A., Lee, M. J., Kim, H. Y., Kim, S., Kim, K., Min, D. S., Yoo, H. C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76757-0 · Cited by 1
“Conversely, pharmacological inhibition of glutamine metabolism has been shown to enhance myeloid-driven antitumor immunity 67,68 .”
Peng, X., Liu, S., & Tao, Y. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00812-1
“Furthermore, inhibition of glutamine metabolism in MDSCs triggers cell death and drives their conversion into inflammatory macrophages [227].”
Implant-associated infection induces systemic immune reprogramming
Yuan, W., Huang, J., Wang, H., Zhang, Y., Zhou, H., Zhang, C., Sun, T., & Song, C. (2026) · Medical Review · doi:10.1515/mr-2026-0039
“Thus, glutaminase inhibitors disrupt MDSC metabolic dependency on glutamine [158], while Arg-1 inhibitors block arginine catabolism and replenish this essential substrate for T-cell activation, collectively attenuating MDSC-mediated immunosuppression and facilitating immune reconstitution [159].”
Amino Acid Metabolism in Health and Disease
Su, Z., Liu, J., Deng, X., Luo, Y., Xue, H., Wang, L., Xing, L., & Wu, T. (2026) · MedComm · doi:10.1002/mco2.70930
“Restriction of total or specific EAAs also alleviates hepatic steatosis in NAFLD, improves metabolic profiles in obesity and T2D, and enhances energy expenditure via fibroblast growth factor 21 upregulation [ 377 ].”
Tumor-responsive mitochondria-targeted DON prodrugs for selective glutamine metabolism inhibition
Kim, T., Oh, S., Jang, E., Jeon, J. S., Baek, M., Song, D., 강서현, Jeong, S., Kim, Y. S., Kim, M., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.181296
Gupta, S., Chahat, C., Kumar, M., Kumar, B., Wahajuddin, M., & Joshi, G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44185-1.00036-7
Bartusik‐Aebisher, D., Raj, D. R. J., Wilk, I., & Aebisher, D. (2026) · Molecules · doi:10.3390/molecules31173124 · Cited by 1
“Additionally, it lowers IDO-associated immunosuppression, and increases antitumour immunity, especially when it is paired with immune checkpoint blockade [85].”
Xu, X., Wu, Y., Yin, K., & Wu, R. (2026) · Nature Communications · doi:10.1038/s41467-026-77775-8
“Consequently, blocking glutamine metabolism by small molecules resulted in decreased tumor growth 9,10 .”
Liu, Y., Sun, I.-M., Creixell, M., Brown, J. S., Kharbanda, S., Lee, J. J., Shahryari, V., Hake, K., O'Hara, J. D., Finn, K. J., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-26-0770
Self-citationMetabolic Reprogramming Of Macrophages In Breast Cancer: Mechanisms And Therapeutic Implications
Zhang, J., & Yang, R. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101376
Wang, S., Fu, Y., & Huang, Y. (2026) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2500179
“Recent research has revealed that the glutamine antagonist JHU083 is capable of inhibiting glutamine metabolism, driving TAMs from the immunosuppres‐ sive M2 type to the anti-tumor M1 type and enhanc‐ ing antigen presentation for T-cell activation (Oh et al., 2020; Praharaj et al., 2024).”
Metabolites and cancer metastasis
Yang, S., Shi, S., Hou, J., Zhang, J., & Su, Z. (2026) · Oncogene · doi:10.1038/s41388-026-03930-6
“Glutamine inhibitors have been reported to not only disrupt tumor cell metabolism but also reprogram the immune landscape, thereby potentiating responses to immunotherapy [103].”
Glutamine metabolism in health and disease
Zhao, J., Lin, Y., Gao, R., Gao, H., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02981-1
“119 Tumor cells, with their high anabolic demands and upregulated glutamine transporters such as SLC1A5 and SLC7A5, often outcompete tumor-in fi ltrating lymphocytes for this critical nutrient.”
Wang, S., Chen, P., Jing, X., Zou, J., Li, L., Jiang, C., Qian, N., Zhang, X., Shi, L., Xu, Y., et al. (2026) · Materials & Design · doi:10.1016/j.matdes.2026.117182
Mitochondrial regulation of tumor-associated macrophage function
Xu, J., Liu, Y., Zhang, H., Yuan, Z., Sheng, Y., Wang, X., Liu, H., Zhong, F., Zhang, H., Xiong, H., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1971517
“Tumor and immune cells compete for glucose, amino acids, lipids, and oxygen, while macrophages can adapt their substrate use to nutrient availability (55, 56).”
Yin, J., Lu, S., Liu, Y., Gong, M., Zha, Y., & Jiang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1928701
Matteo, S. D., & Gnocchi, D. (2026) · Biology · doi:10.3390/biology15191790
“In parallel, glutamine deficiency promotes Treg function, supporting macrophage polarization into the M2 phenotype, and enhancing the suppressive activity of MDSCs [195,197,198].”
Wang, M., Chen, J., 吴中华, Wang, Z., Zhong, Z., & Zhong, Y. (2026) · Biomarker Research · doi:10.1186/s40364-026-01011-0
“In preclinical studies, pharmacological blockade of glutamine metabolism using inhibitors such as JHU083 induced energy insufficiency and ER stress in MDSCs, subsequently triggering programmed cell death and reducing the abundance of immunosuppressive cells in the microenvironment [90, 91].”
Metabolic processes and microenvironmental regulation in leukemia
Chang, B., Wang, Y., Li, Z., Zhao, M., Deng, C., Ren, Y., Li, Q., Sun, X., & Wang, L. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004226
Macrophage biology and immunoregulation in health and disease
Zhao, H., Chou, Y.-J., & Huang, S. C. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01486-9
Tang, L., 周浩玲, & Liu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1962178
Lu, M., Zhang, L., Feng, W., Hu, Q., Bian, J., & Wang, J. (2026) · Immunology · doi:10.1111/imm.70221
Metadata
- Authors
- Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., Englert, J. M., Arwood, M. L., Wen, J., Chan-Li, Y., Tenora, L., Majer, P., Rais, R., Slusher, B. S., Horton, M. R., & Powell, J. D.
- Affiliations
- Johns Hopkins University (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- UPMC Enterprises (United States) (US)
- Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry (CZ)
- Corresponding author
- Powell, Jonathan D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-06-15
- Volume
- 130
- Issue
- 7
- Pages
- 3865-3884
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3020598614
- Cited by
- 456
- References
- 66
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 77 · 2023: 89 · 2022: 65 · 2021: 49 · 2020: 18
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH Office of the Director (R01CA229451, S10 OD016374, R01HL141490, R01AI077610, R01CA226765)
- Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (N/A)
- Under Armour Women’s Health & Breast Cancer Innovation Grants (N/A)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glutamine metabolism, myeloid-derived suppressor cells, tumor microenvironment, tumor-associated macrophages, immunogenic cell death, granulocyte colony-stimulating factor, IDO, kynurenine, immunometabolism, metastasis, antitumor immunity, small molecule inhibitors
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Female, Glutamine, Immunity, Cellular, Immunotherapy, Macrophages, Male, Mice, Inbred BALB C, Neoplasms, Experimental, Mice, Knockout, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.